Cargando…
ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer
BACKGROUND: Small cell lung cancer (SCLC) is a more aggressive subtype of lung cancer that often results in rapid tumor growth, early metastasis, and acquired therapeutic resistance. Consequently, such phenotypical characteristics of SCLC set limitations on viable procedural options, making it diffi...
Autores principales: | Szczepanski, Aileen Patricia, Zhao, Zibo, Sosnowski, Tori, Goo, Young Ah, Bartom, Elizabeth Thomas, Wang, Lu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362484/ https://www.ncbi.nlm.nih.gov/pubmed/32669118 http://dx.doi.org/10.1186/s13073-020-00760-3 |
Ejemplares similares
-
Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer
por: Tsuboyama, Natsumi, et al.
Publicado: (2022) -
MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer
por: Tsuboyama, Natsumi, et al.
Publicado: (2022) -
Emerging multifaceted roles of BAP1 complexes in biological processes
por: Szczepanski, Aileen Patricia, et al.
Publicado: (2021) -
Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex
por: Balasubramani, Anand, et al.
Publicado: (2015) -
CARM1-mediated methylation of ASXL2 impairs tumor-suppressive function of MLL3/COMPASS
por: Zhao, Zibo, et al.
Publicado: (2022)